An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome-Reference-Cited by-同舟云学术

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

Published:2008-02-12 Issue:2 Volume:5 Page:e35
ISSN:1549-1676
Container-title:PLoS Medicine
language:en
Short-container-title:PLoS Med

Author:

Ebert Benjamin L,Galili Naomi,Tamayo Pablo,Bosco Jocelyn,Mak Raymond,Pretz Jennifer,Tanguturi Shyam,Ladd-Acosta Christine,Stone Richard,Golub Todd R,Raza Azra

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference36 articles.

1. DeangeloDStoneR 2005 Myelodysplastic syndromes: biology and treatment Philadelphia Elsevier 1195 1208

2. Myelodysplasia.;N Engl J Med,1999

3. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.;N Engl J Med,2006

4. Efficacy of lenalidomide in myelodysplastic syndromes.;N Engl J Med,2005

5. Phase II study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q.;Blood,2008

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia;2024-08-07

2. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide;Nature Communications;2024-06-20

3. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications;European Journal of Haematology;2024-01-31

4. Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease;Blood Journal;2023-12-20

5. Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomide;2023-10-20